Two Brothers. One Mission.

She went in for a routine procedure. She developed C. diff, then sepsis, then spent months in hospital. Nobody could tell us where it came from, and over two decades later, most hospitals still can't.

Dirk spent six years at McMaster under Gerry Wright, a top antimicrobial resistance researcher, using DNA sequencing to find infectious disease and resistance genes across blood, sputum, wastewater, and World War II-era military latrines. The science worked. It was just far too expensive to run continuously.

Kurt spent the last decade plus building toward exactly this: door-to-door pest control sales, investment banking, then seven years as an investor, most recently at Carlyle, where he led diligence across 350+ businesses and put over $3Bn behind the ones he believed in. Now he's applying those learnings to build his own: creating a commercial model for a market that doesn't exist yet, so Dirk's science reaches the hospitals that need it most.

Dirk's doctoral research produced a breakthrough that cuts certain sequencing costs twentyfold, making proactive genomic intelligence commercially viable for the first time. So they took the leap with one mission: that no grandmother seeking care should have to worry about a preventable infection.

Claryx exists to fundamentally change the way hospital-acquired infections are detected, traced, and stopped.